Fluid-phase markers in the basolateral endocytic pathway accumulate in response to the actin assembly-promoting drug Jasplakinolide.
To investigate the role of filamentous actin in the endocytic pathway, we used the cell-permeant drug Jasplakinolide (JAS) to polymerize actin in intact polarized Madin-Darby canine kidney (MDCK) cells. The uptake and accumulation of the fluid-phase markers fluorescein isothiocyanate (FITC)-dextran and horseradish peroxidase (HRP) were followed in JAS-treated or untreated cells with confocal fluorescence microscopy, biochemical assays, and electron microscopy. Pretreatment with JAS increased the uptake and accumulation of fluid-phase markers in MDCK cells. JAS increased endocytosis in a polarized manner, with a marked effect on fluid-phase uptake from the basolateral surface but not from the apical surface of polarized MDCK cells. The early uptake of FITC-dextran and HRP was increased more than twofold in JAS-treated cells. At later times, FITC-dextran and HRP accumulated in clustered endosomes in the basal and middle regions of JAS-treated cells. The large accumulated endosomes were similar to late endosomes but they were not colabeled for other late endosome markers, such as rab7 or mannose-6-phosphate receptor. JAS altered transport in the endocytic pathway at a later stage than the microtubule-dependent step affected by nocodazole. JAS also had a notable effect on cell morphology, inducing membrane bunching at the apical pole of MDCK cells. Although other studies have implicated actin in endocytosis at the apical cell surface, our results provide novel evidence that filamentous actin is also involved in the endocytosis of fluid-phase markers from the basolateral membrane of polarized cells.
Shurety
W
W
Centre for Molecular and Cellular Biology, University of Queensland, Brisbane, Queensland 4072, Australia.
Stewart
N L
NL
Stow
J L
JL
D000199:Actins / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D015415:Biomarkers; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects / Q000648:ultrastructure; D016764:Cell Polarity / Q000187:drug effects*; D047630:Depsipeptides; D003911:Dextrans / Q000493:pharmacokinetics; D004285:Dogs; D004705:Endocytosis / Q000187:drug effects / Q000502:physiology*; D016650:Fluorescein-5-isothiocyanate / Q000031:analogs & derivatives / Q000378:metabolism / Q000493:pharmacokinetics; D006735:Horseradish Peroxidase / Q000493:pharmacokinetics; D007668:Kidney / Q000166:cytology; D015739:Nocodazole / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000378:metabolism / Q000494:pharmacology; D011108:Polymers; D014168:Transferrin / Q000378:metabolism / Q000493:pharmacokinetics
D000199:Actins; D015415:Biomarkers; D047630:Depsipeptides; D003911:Dextrans; D010456:Peptides, Cyclic; D011108:Polymers; D014168:Transferrin; C015219:fluorescein isothiocyanate dextran; C057531:jasplakinolide; D006735:Horseradish Peroxidase; D016650:Fluorescein-5-isothiocyanate; D015739:Nocodazole